News about Market

Biocon Announces US Commercial Launch of Yesafili, a Biosimilar to Regeneron's Eylea 2 mg

Biocon has launched Yesafili, an interchangeable biosimilar to Eylea 2 mg in the US, expanding access to treatment for Age-related Macular Degeneration (AMD) and other retinal diseases.

Market | 03/08/2026 | By News Bureau

US FDA Expands Approval of Novartis' Pluvicto for Earlier Treatment of Advanced Prostate Cancer

The US FDA has approved Novartis' Pluvicto for use in patients with PSMA-positive metastatic hormone-sensitive prostate cancer, expanding access to the radioligand therapy at an earlier stage of disease.

Market | 03/08/2026 | By News Bureau |  139

Sun Pharma Reports Q1FY27 Results

Sun Pharma reported a 10.1 percent YoY rise in Q1 FY27 sales to INR 151,836 million, while net profit increased to INR 28,948 million, driven by strong business growth.

Market | 01/08/2026 | By News Bureau |  256

Lupin Launches Generic Sugammadex Injection in the US Following FDA Approval

Lupin launches Sugammadex Injection in the United States after receiving US FDA approval for its Abbreviated New Drug Application. The bioequivalent version of Merck's Bridion Injection is indicated for reversing neuromuscular blockade in adult and paediatric patients aged two years and older undergoing surgery.

Market | 31/07/2026 | By News Bureau

European Commission Approves Pfizer-BioNTech's XFG-Adapted COVID-19 Vaccine for 2026-27 Season

The European Commission has approved Pfizer and BioNTech's monovalent XFG-adapted COVID-19 vaccine for the 2026–27 vaccination season that authorised for people aged six months and above, is designed to enhance protection against currently circulating SARS-CoV-2 variants and will be supplied across the European Union and selected European countries.

Market | 31/07/2026 | By News Bureau |  139

GSK to Establish New Global R&D Centre in Cambridge to Accelerate Drug Discovery

GSK will establish a 300,000 sq. ft. global R&D centre at the Cambridge Biomedical Campus, bringing together more than 1,000 scientists to accelerate medicines discovery through closer collaboration with leading academic, clinical and biotechnology partners.

Market | 30/07/2026 | By News Bureau

Piramal Pharma Reports Q1 FY27 Results

Piramal Pharma has reported its standalone and consolidated Q1 FY27 financial results, highlighting its performance for the quarter ended June 30, 2026.

Market | 30/07/2026 | By News Bureau |  129

HAB Pharmaceuticals Charts Growth Path, Targets INR 2,500 to 3,000 Crore Revenue by 2030

HAB Pharmaceuticals is expanding its manufacturing and R&D capabilities while strengthening its specialty product portfolio and global regulatory footprint as it targets revenues of INR 2,500–3,000 crore by 2030.

Market | 29/07/2026 | By News Bureau |  144

Glenmark Launches Generic Sugammadex Injection in US

Glenmark has launched generic Sugammadex Injection in the US, a bioequivalent and therapeutically equivalent version of Merck's BRIDION Injection.

Market | 29/07/2026 | By News Bureau

Indoco Remedies Reports Improved Q1 FY27 Revenue and EBITDA

Indoco Remedies reported higher revenue and improved EBITDA in Q1 FY27, supported by the strong performance of its domestic formulations business and steady progress in international formulations and APIs.

Market | 28/07/2026 | By News Bureau